Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meetings, 11235-11236 [2017-03277]
Download as PDF
<![CDATA[
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 82, No. 33 / Tuesday, February 21, 2017 / Notices
Contact Person: Reigh-Yi Lin, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–827–6009,
lin.reigh-yi@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 16–
366—Dual Purpose with Dual Benefit:
Research in Biomedicine and Agriculture.
Date: March 21, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Tera Bounds, DVM, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3214,
MSC 7808, Bethesda, MD 20892, 301–435–
2306, boundst@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Risk, Prevention and Health
Behavior Overflow.
Date: March 21, 2017.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Stacey C. FitzSimmons,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
MSC 7808, Bethesda, MD 20892, (301) 451–
9956, fitzsimmonss@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Urology and
Urogynecology Small Business Applications.
Date: March 21, 2017.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Ganesan Ramesh, Ph.D.,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Dr.,
Room 2182, MSC 7818, Bethesda, MD 20892,
ganesan.ramesh@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics in drug discovery and
clinical field studies.
Date: March 21, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Liangbiao Zheng, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3202,
MSC 7808, Bethesda, MD 20892, 301–996–
5819, zhengli@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
VerDate Sep<11>2014
17:15 Feb 17, 2017
Jkt 241001
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 14, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03281 Filed 2–17–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by emailing the indicated licensing
contact at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive, Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive any unpublished
information.
SUPPLEMENTARY INFORMATION: The
following inventions are available for
licensing in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Technology description
follows.
SUMMARY:
Methods for Improving Drug Delivery
to the Central Nervous System
The invention relates to the uses of
the tricyclic antidepressant
amitriptyline, its bioactive metabolites,
and other LPA1R activators to improve
the bioavailability and delivery of
therapeutics to the central nervous
system. This invention demonstrates
that amitriptyline and other agents
selectively decrease P-glycoprotein (Pgp) transport activity by ligand
activation of lysophosphatidic acid 1
receptor (LPA1R) at the blood-brain
barrier. P-gp is an effective target for
increasing drug delivery to the brain
(CNS) for two major reasons: (1) Its
substrates include a large portion of onthe-market drugs, including
chemotherapeutics, and (2) its
directionality results in a net efflux of
drugs from the brain. Additionally,
specifically targeting P-gp through
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
11235
LPA1R activation bypasses the clinical
challenges resulting from the toxicity of
substrate inhibitors of P-gp. This
invention describes the inhibition of
drug efflux by P-gp transport; thus, coadministration of therapeutics with
amitriptyline and other LPA1R
activators provides a method for
increasing drug delivery to the CNS, and
improving overall drug efficacy.
Moreover, drug delivery to other barrier
tissues will also be enhanced where a
similar LPA1R–P-gp activity
relationship exists.
Potential Commercial Applications:
• Drug Delivery to the CNS.
• Co-administration of therapeutics.
• Blood-brain-barrier permeability.
Development Stage:
• Early stage.
Inventors: Ronald Cannon and David
Banks (NIEHS).
Publications:
• Cannon et al., Neurosci Lett. 2017
Feb 3;639:103–113 doi: 10.1016/
j.neulet.2016.12.049.
• Mesev, et al., Mol Pharmacol. 2017
Jan 24. pii: mol.116.107169. doi:
10.1124/mol.116.107169.
• More, et al., J Cereb Blood Flow
Metab. 2016 May 18. pii:
0271678X16650216.
• Miller, et. al, Curr Pharm Des.
2014;20(10):1463–71. Review.
• Cartwright, et al., J Cereb Blood
Flow Metab. 2013 Mar;33(3):381–8. doi:
10.1038/jcbfm.2012.174.
Intellectual Property: HHS Reference
No. E–179–2065/0 and/1; U.S.
Provisional Patent Applications 62/
332,888 filed May 6, 2016, and 62/
453,718 filed February 2, 2017,
respectively.
Licensing Contact: Michael
Shmilovich, Esq., CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Dated: February 10, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2017–03306 Filed 2–17–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
E:\FR\FM\21FEN1.SGM
21FEN1
11236
Federal Register / Vol. 82, No. 33 / Tuesday, February 21, 2017 / Notices
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
sradovich on DSK3GMQ082PROD with NOTICES
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; NICHD T35
Teleconference Review.
Date: March 10, 2017.
Time: 1:30 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6710B
Rockledge Drive, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Sherry L. Dupere, Ph.D.,
Chief, Scientific Review Branch, Scientific
Review Branch, Eunice Kennedy Shriver
National Institute of Child Health and
Human Development, NIH, National
Institutes of Health, 6710B Rockledge Drive,
Bethesda, MD 20817, 301–451–3415,
duperes@mail.nih.gov.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Learning Disabilities
Center.
Date: April 20–21, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Beacon Hotel and Corporate
Quarters, 1615 Rhode Island Avenue NW.,
Washington, DC 20036.
Contact Person: Marita R. Hopmann, Ph.D.,
Scientific Review Officer, Division of
Scientific Review, National Institute of Child
Health and Human Development, National
Institutes of Health, 6710B Rockledge Drive,
Bethesda, MD 20817, (301) 435–6911,
hopmannm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: February 14, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03277 Filed 2–17–17; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:15 Feb 17, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications/
contract proposals and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications/
contract proposals, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Provocative Question 2.
Date: March 15, 2017.
Time: 11:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W032, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Jun Fang, Ph.D., Scientific
Review Officer, Research Technology and
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W246, Bethesda, MD 20892–9750,
240–276–5460, jfang@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Provocative Question 4.
Date: March 16, 2017.
Time: 12:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W556, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Bratin K. Saha, Ph.D.,
Scientific Review Officer, Program
Coordination and Referral Branch, Division
of Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W556, Bethesda, MD 20892–9750,
240–276–6411, sahab@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Cell and
Animal Models for Researching Disparities.
Date: March 21, 2017.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W554, Rockville, MD 20850 (Telephone
Conference Call).
PO 00000
Frm 00066
Fmt 4703
Sfmt 9990
Contact Person: Christopher L. Hatch,
Ph.D., Chief, Program Coordination and
Referral Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W554,
Rockville, MD 20892–9750, 240–276–6454,
ch29v@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 14, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03282 Filed 2–17–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the President’s Cancer
Panel, March 27, 2017, 9:00 a.m. to
March 28, 2017, 1:00 p.m., Kimpton
Hotel Palomar, Philadelphia, PA 19103
which was published in the Federal
Register on February 1, 2017, 82 FR
8944.
This meeting notice is amended to
change the ending date and time from
March 28, 2017 at 1:00 p.m. to March
27, 2017 at 4:30 p.m. The agenda has
also been amended as follows:
‘‘Welcome and Introductions; Session 1:
The Pricing and Payment Landscapes—
Framing the Issues—1 and 2; Session 2:
Cancer Drug Value/Intervention
Framework; Public Comment; Session 3:
High-Cost/High Value Drugs; Session 4:
High-Cost/Modest Value Drugs; Public
Comment; Wrap-Up and Next Steps.’’
The meeting is open to the public.
Dated: February 14, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03274 Filed 2–17–17; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\21FEN1.SGM
21FEN1
]]>Agencies
[Federal Register Volume 82, Number 33 (Tuesday, February 21, 2017)]
[Notices]
[Pages 11235-11236]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03277]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National Institute of Child Health & Human
Development; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
[[Page 11236]]
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Child Health and Human
Development Special Emphasis Panel; NICHD T35 Teleconference Review.
Date: March 10, 2017.
Time: 1:30 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6710B Rockledge Drive,
Bethesda, MD 20817 (Telephone Conference Call).
Contact Person: Sherry L. Dupere, Ph.D., Chief, Scientific
Review Branch, Scientific Review Branch, Eunice Kennedy Shriver
National Institute of Child Health and Human Development, NIH,
National Institutes of Health, 6710B Rockledge Drive, Bethesda, MD
20817, 301-451-3415, duperes@mail.nih.gov.
Name of Committee: National Institute of Child Health and Human
Development Special Emphasis Panel; Learning Disabilities Center.
Date: April 20-21, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Beacon Hotel and Corporate Quarters, 1615 Rhode Island
Avenue NW., Washington, DC 20036.
Contact Person: Marita R. Hopmann, Ph.D., Scientific Review
Officer, Division of Scientific Review, National Institute of Child
Health and Human Development, National Institutes of Health, 6710B
Rockledge Drive, Bethesda, MD 20817, (301) 435-6911,
hopmannm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.864,
Population Research; 93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation Research; 93.209,
Contraception and Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: February 14, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-03277 Filed 2-17-17; 8:45 am]
BILLING CODE 4140-01-P
